2024. Evaluation of Changes in Laboratory Parameters from a Phase 2b Trial of Zasocitinib (TAK-279), an Oral, Selective TYK2 Inhibitor, in Patients with Moderate-to-Severe Plaque Psoriasis. SKIN The Journal of Cutaneous Medicine. 8, 6 (Nov. 2024), s442. DOI:https://doi.org/10.25251/skin.8.supp.442.